ADC Therapeutics Q3 Adj. EPS $(0.41) Beats $(0.63) Estimate, Sales $14.49M Miss $15.99M Estimate
ADC Therapeutics Q3 Adj. EPS $(0.41) Beats $(0.63) Estimate, Sales $14.49M Miss $15.99M Estimate
ADC Therapeutics第三季度調整後的每股收益（0.41美元）超過了美元（0.63美元）的預期，銷售額1449萬美元未達到預期的1599萬美元
ADC Therapeutics (NYSE:ADCT) reported adjusted quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.63) by 34.92 percent. This is a 415.38 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $14.49 million which missed the analyst consensus estimate of $15.99 million by 9.36 percent. This is a 81.01 percent decrease over sales of $76.32 million the same period last year.
ADC Therapeutics（紐約證券交易所代碼：ADCT）報告調整後的每股季度虧損爲0.41美元（0.41美元），比分析師共識估計的0.63美元（0.63美元）高出34.92％。這比去年同期的每股收益0.13美元下降了415.38％。該公司公佈的季度銷售額爲1449萬美元，比分析師普遍估計的1,599萬美元低9.36％。這比去年同期的7,632萬美元的銷售額下降了81.01％。
資訊熱榜
更新時間